In‐hospital outcomes after transcatheter edge‐to‐edge mitral valve repair in patients with chronic kidney disease: An analysis from the 2010–2016 National inpatient sample

摘要

Abstract Objectives To assess the outcomes following transcatheter edge‐to‐edge mitral valve repair (TMVr) in patients with chronic kidney disease (CKD). Background Percutaneous TMVr is beneficial in high surgical risk patients with severe mitral regurgitation (MR). However, those with CKD are not well studied. Methods Utilizing the International Classification of Disease (ninth and tenth revision, clinical modification codes) and the Nationwide Inpatient Sample database, we identified 9,228 patients who underwent TMVr during 2010–2016, including those with no or mild CKD (group 1, n?=?6,654 [72.11%]), moderate or severe CKD (group 2, n?=?2,125 [23.03%]) and end‐stage renal disease (ESRD) on dialysis (group 3, n?=?449 [4.86%]). In‐hospital clinical outcomes, length of stay and cost were assessed. Results In‐hospital mortality increased numerically as CKD severity increased, but not statistically different between groups (1.8, 3.3, and 4.5% respectively in group 1, 2, and 3, p?=?.07). Moderate to severe CKD (group 2) was an independent predictor of acute renal failure requiring hemodialysis (ARFD) (OR: 3.51, CI: 2.33–5.28, p?